Article
New Xarelto (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Prog
Rating:
0.0
Views:
133
Likes:
1
Library:
1
Data includes several analyses from the landmark VOYAGER PAD trial, including findings in high-risk patients with critical limb ischemia (CLI) after lower-extremity revascularization (LER) XARELTO® has the potential to be the first anticoagulant in 20 years to show a benefit in patients with PAD after LER[i] The comprehensive PAD program within EXPLORER continues to generate new findings that may shift the way symptomatic and chronic patients are managed
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value